376 results on '"van Leeuwen, Flora E."'
Search Results
2. The mediating role of health behaviors in the association between depression, anxiety and cancer incidence: an individual participant data meta-analysis
3. Cardiovascular screening outcomes in the Dutch survivorship care program for Hodgkin lymphoma survivors
4. Doxorubicin Exposure and Breast Cancer Risk in Survivors of Adolescent and Adult Hodgkin Lymphoma
5. Psychosocial factors, health behaviors and risk of cancer incidence: Testing interaction and effect modification in an individual participant data meta‐analysis
6. Prevalence of neoplasia at colonoscopy among testicular cancer survivors treated with platinum‐based chemotherapy
7. Reply to G. Wang et al
8. Risk of male breast cancer after Hodgkin lymphoma
9. Depression, anxiety, and the risk of cancer: An individual participant data meta‐analysis
10. Urinary incontinence more than 15 years after premenopausal risk‐reducing salpingo‐oophorectomy: a multicentre cross‐sectional study
11. Second Malignancy Risk After Treatment of Hodgkin Lymphoma
12. The Areola study: design and rationale of a cohort study on long-term health outcomes in women with implant-based breast reconstructions
13. Risk Factors for Primary Bone Cancer After Childhood Cancer: A PanCare Childhood and Adolescent Cancer Survivor Care and Follow-Up Studies Nested Case-Control Study
14. Supplementary Table from Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy
15. Supplementary Figure from Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy
16. Supplementary Figure from Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy
17. Supplementary Data from Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy
18. Data from Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy
19. Supplementary Table from Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy
20. Supplementary Table from Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy
21. Supplementary Table from Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy
22. Supplementary Data from Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy
23. Supplementary Table from Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy
24. Supplementary Table from Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy
25. Data from Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy
26. Supplementary Figure from Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy
27. Supplementary Figure from Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy
28. Supplementary Table from Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy
29. Supplementary Table from Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy
30. Cardiovascular Disease in Testicular Cancer Survivors: Identification of Risk Factors and Impact on Quality of Life
31. Surgical outcomes following breast reconstruction in patients with and without a history of chest radiotherapy for Hodgkin lymphoma: a multicentre, matched cohort study
32. Sexual functioning more than 15 years after premenopausal risk-reducing salpingo-oophorectomy
33. Supplementary Table S2 from Germline BRCA-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity
34. Data from Variation in Mutation Spectrum Partly Explains Regional Differences in the Breast Cancer Risk of Female BRCA Mutation Carriers in the Netherlands
35. Supplementary Fig. S1 from Germline BRCA-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity
36. Supplementary Table S1 from Germline BRCA-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity
37. Supplementary Fig. S2 from Germline BRCA-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity
38. Supplementary Fig. S5 from Germline BRCA-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity
39. Supplementary Fig. S5 from Germline BRCA-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity
40. Supplementary Tables 1 through 5 from Variation in Mutation Spectrum Partly Explains Regional Differences in the Breast Cancer Risk of Female BRCA Mutation Carriers in the Netherlands
41. Supplementary Tables 1-4 from Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers
42. Supplementary Fig. S2 from Germline BRCA-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity
43. Supplementary Fig. S4 from Germline BRCA-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity
44. Data from Variation in Mutation Spectrum Partly Explains Regional Differences in the Breast Cancer Risk of Female BRCA Mutation Carriers in the Netherlands
45. Data from Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers
46. Supplementary Fig. S3 from Germline BRCA-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity
47. Supplementary Tables 1-4 from Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers
48. Supplementary Tables 1 through 5 from Variation in Mutation Spectrum Partly Explains Regional Differences in the Breast Cancer Risk of Female BRCA Mutation Carriers in the Netherlands
49. Supplementary Material and Methods from Germline BRCA-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity
50. Supplementary Fig. S4 from Germline BRCA-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.